ArticleAesthetic plastic surgery2026
Medial Epicanthoplasty: A Modified Inverted Z-Plasty Technique to Create Ethnic Appropriate Medial Canthal Configuration.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe medial epicanthal fold is a common anatomical feature in Asian populations, often coexisting with single eyelid configurations. Epicanthoplasty, combined with blepharoplasty, is a standard cosmetic procedure to create a larger palpebral fissure, yet achieving optimal outcomes with undetectable scarring and preserved canthal function remains challenging. This study develops an advanced inverted Z-plasty technique incorporating biomechanical principles to achieve superior ethnic aesthetics and inconspicuous scarring through minimal tissue disruption.
methodsFrom February 2022 to June 2025, 17 patients, comprising 15 females and two males, underwent a novel epicanthoplasty technique. The age distribution of the patients ranged from 17 to 46 years. The severity of the epicanthal fold was categorized into three grades: mild, moderate, and severe. Specifically, 3 cases were classified as mild, eight as moderate, and six as severe. A modified inverted Z-plasty technique, incorporating medial canthal tendon (MCT) folding, was utilized to correct the medial epicanthal fold, which was performed concurrently with double eyelid surgery. Postoperative follow-up ranged from 3 to 39 months, averaging 18.5 months. Scar quality was assessed using the Vancouver Scar Scale (VSS). Aesthetic outcomes were evaluated using patient-reported visual analog scale (VAS) scores.
resultsThe modified inverted Z-plasty technique demonstrated excellent outcomes in 17 Asian patients, with all cases achieving imperceptible scarring (VSS score ≤ 1). Postoperatively, all patients exhibited a notable improvement in their epicanthal folds. The mean visual analog scale (VAS) score was 4.8 (4.5-5.0). Biomechanical modifications effectively widened the palpebral fissure to achieve an aesthetic outcome consistent with Asian preferences, while simultaneously ensuring the complete preservation of lacrimal lake function, resulting in 100% patient satisfaction. All observed complications were transient and well-tolerated.
conclusionThe modified inverted Z-epicanthoplasty demonstrates safety and efficacy in medial epicanthal fold correction across varying severity grades, delivering aesthetically durable, ethnic-appropriate results with clinically invisible scarring. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
41491328What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.